Date published: 2025-9-11

021-6093-6350

SCBT Portrait Logo
Seach Input

MNS Blood Group Antigens激活剂

The MNS blood group system is one of the human blood group systems and was one of the first to be discovered, initially described in the early 20th century. It is named after the two antithetical antigens, M and N, that were first identified. These antigens are glycoproteins located on the surface of red blood cells and serve as markers that can be recognized by the immune system. In addition to the M and N antigens, this blood group system also encompasses other antigens like S, s, and U among others. The genetic basis for the MNS system lies in two closely linked genes, GYPA and GYPB, which encode the glycophorin A and glycophorin B proteins, respectively. These proteins are the carriers of the M, N, S, and s antigens on the red blood cell membrane.

MNS Blood Group Antigens Activators include signaling molecules, metabolic intermediates, and enzyme inhibitors can also come under the category of MNS Blood Group Antigens Activators as they can indirectly influence the activity and expression of these antigens. In many cases, the influence is a result of the molecule's effect on cellular metabolism, the endoplasmic reticulum-Golgi transport system, or epigenetic regulation. Specific metabolic pathways or signaling cascades, when modified by these activators, can lead to changes in the glycosylation patterns of MNS antigens. Compounds like Brefeldin A affect protein transport between the endoplasmic reticulum and the Golgi, thereby influencing the glycosylation patterns, including those of MNS antigens. Similarly, molecules like sialic acid analogs can be incorporated into glycoproteins, thereby influencing the sialylation patterns and potentially the properties of MNS blood group antigens.

関連項目

Items 1 to 10 of 11 total

展示:

产品名称CAS #产品编号数量价格应用排名

N-Acetyl-D-galactosamine

1811-31-0sc-221979
sc-221979A
sc-221979C
sc-221979B
sc-221979D
10 mg
100 mg
1 g
5 g
50 g
¥564.00
¥846.00
¥2956.00
¥11508.00
¥14667.00
(0)

当引入细胞时,它可能会增加 O-GalNAc 型糖基化,这可能会对 MNS 抗原的表达产生影响。

hydroxychloroquine

118-42-3sc-507426
5 g
¥632.00
1
(0)

它主要是一种抗疟疾药物,会影响内体酸化,并有可能影响与 MNS 抗原结构有关的聚糖加工。

Ibuprofen

15687-27-1sc-200534
sc-200534A
1 g
5 g
¥587.00
¥970.00
6
(0)

它被广泛用于缓解疼痛和炎症,可抑制COX-1和COX-2酶,从而可能影响与糖基化模式相关的细胞信号传导,包括MNS抗原的信号传导。

Naproxen

22204-53-1sc-200506
sc-200506A
1 g
5 g
¥271.00
¥451.00
(1)

另一种常见的非甾体抗炎药可能会通过抑制 COX 对糖基化产生类似的影响,这可能会影响 MNS 抗原。

Aspirin

50-78-2sc-202471
sc-202471A
5 g
50 g
¥226.00
¥463.00
4
(1)

除了抑制 COX 酶外,阿司匹林还对细胞信号传导产生其他复杂影响,理论上可影响 MNS 抗原的活性。

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
¥316.00
¥417.00
18
(1)

用于治疗各种炎症性疾病时,它可能会影响前列腺素水平,从而对糖基化模式(包括与 MNS 抗原相关的糖基化模式)产生二次影响。

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
¥2843.00
¥5585.00
9
(1)

他汀类药物是最常用的处方药之一,有可能通过影响细胞代谢来影响糖基化,从而影响 MNS 抗原结构。

Simvastatin

79902-63-9sc-200829
sc-200829A
sc-200829B
sc-200829C
50 mg
250 mg
1 g
5 g
¥338.00
¥982.00
¥1489.00
¥4896.00
13
(1)

它因具有降低胆固醇的作用而闻名,也可能影响细胞信号通路,从而间接影响糖基化,包括 MNS 抗原的糖基化。

Rosuvastatin

287714-41-4sc-481834
10 mg
¥1602.00
8
(0)

这种他汀类药物的作用机制与其他他汀类药物相似,但药效更强。它对糖基化模式(包括 MNS 抗原的糖基化模式)的影响尚未得到充分研究。

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
¥316.00
¥993.00
¥3746.00
12
(1)

与其他他汀类药物一样,它能抑制 HMG-CoA 还原酶,影响胆固醇的合成,并可能影响细胞糖基化模式,包括 MNS 抗原的糖基化模式。